Business
CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
VIENNA, Va., August 13, 2025--CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia.
About this update from Cel-sci Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":240,"url":"https://media.zenfs.com/en/business-wire.com/b999c04b1cf75d1cd302ff2d2cdcfbea"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H7QO_y32whg0r7ULcwTWIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b999c04b1cf75d1cd302ff2d2cdcfbea","width":480,"height":240}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Memorandum of Understanding (MOU) signed with a leading Saudi Arabian pharma company which submitted the Breakthrough Medicine Designation to the Saudi Food and Drug Authority (SFDA)","length":182,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Increasing interest in CEL-SCI from Saudi investment funds as Multikine advances through regulatory and drug distribution channels","length":130,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":312,"olType":false},{"type":"text","content":"VIENNA, Va., August 13, 2025--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that a Breakthrough Medicine Designation application has been filed with the Saudi Food and Drug Authority (SFDA) for Multikine* (Leukocyte Interleukin, Injection) in the Kingdom of Saudi Arabia by one of the Kingdom’s premier pharmaceutical and healthcare companies. CEL-SCI has signed a Memorandum of Understanding (MOU) with this Saudi pharma company for the commercialization of Multikine in Saudi Arabia. A final partnership agreement is expected during the 3rd quarter of 2025.","length":587,"tagName":"p"},{"type":"text","content":"Multikine is a cancer immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated head and neck cancer. Its goal is to activate a person’s immune system to fight cancer before the ravages of surgery, radiation and chemotherapy have weakened the immune system. In the world’s largest head and neck cancer Phase 3 study, Multikine increased the 5-year survival rate of the target patient population to 73% vs 45% in patients treated with standard of care alone and halved the risk of death from 55% to 27%.","length":542,"tagName":"p"},{"type":"text","content":"According to the SFDA, the response time to a Breakthrough Medic...